Neurobehavioral Correlates of Caffeine on Anxiety, Avoidance and Interoception in Healthy Individuals and Panic Disorder.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-29

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current study is a placebo-controlled, double-blind, randomized controlled study using a cross-over design, including Healthy Controls (HC) and participants with Panic Disorder (PD).

The primary aim of the study is to investigate the neural correlates and behavioral effects of caffeine (versus placebo), and its impact on emotional reactivity, decision-making, and interoception, and compare the effects in individuals with PD vs HCs. Subjective anxiety and the occurrence of panic attacks will also be measured. Multimodal neuroimaging methods, such as structural and functional MRI, will be used to address the aims of the study.

Emotional reactivity, emotional decision-making and interoception will be measured with experimental tasks in a 7 Tesla (7T) magnetic resonance (MR) scanner, jointly with measures of skin conductance, heart rate, respiratory rate, and self-reported ratings of anxiety and interoception.

Emotional reactivity will be assessed using emotional and neutral faces. Emotional decision-making will be assessed with an approach-avoidance conflict task. Changes in interoception (bodily sensation, such as pulse and respiration) will be explored using a task in which participants are asked to focus on their breathing or an external stimulus. Caffeine effects on brain resting-state activity will also be assessed. All tasks will be conducted while in the 7T MR scanner.

A secondary aim of the study is to examine the impact of genetic variability in the adenosine A2A receptor (ADORA2A) genotype (e.g., rs5751876 T/T) on the effects of caffeine (vs placebo), as ADORA2A genotype has previously been associated with elevated caffeine-induced anxiety.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Caffeine on Anxiety, Emotional Processing, Approach-avoidance Behavior, and Interoception in Panic Disorder

NCT05261594

Panic Disorder Healthy

COMPLETED NA

Neurobiological Mechanisms in Panic Disorder

NCT00103987

Panic Disorder

COMPLETED

Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety

NCT02153944

Anxiety Disorder

COMPLETED PHASE4

Neural Effects of Cognitive-behaviour Therapy in Panic Disorder

NCT03251235

Panic Disorder

COMPLETED NA

Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response

NCT02372110

Anxiety

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Given the novelty of the intended study and the lack of previous neuroimaging and emotion-related behavioral studies on caffeine effects in HCs and PD, analyses will be exploratory without directed hypotheses.

It is intended to conduct between-group analyses (HCs vs PD) in the two conditions (caffeine versus placebo), as well as within-group analyses in HCs and PD separately. Between-group analyses will also be conducted between individuals with different ADORA2A genotypes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Panic Disorder Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

The study entails two sessions with a cross-over design. Participants will be randomized to start with either the caffeine condition or the placebo condition.

The study includes two arms: (a) participants with Panic Disorder (anticipated n = 50) and (b) Healthy controls (anticipated n = 50). Both arms (Panic Disorder and Healthy controls) will complete both conditions with the two sessions (caffeine and placebo condition) in randomized order.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Panic Disorder

Participants will be randomized to start with either the caffeine condition or the placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).

Group Type OTHER

Caffeine

Intervention Type DIETARY_SUPPLEMENT

Caffeine capsule 250 mg, oral intake

Placebo

Intervention Type DRUG

Placebo capsule, oral intake

Healthy controls

Participants will be randomized to start with either the caffeine condition or the placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).

Group Type OTHER

Caffeine

Intervention Type DIETARY_SUPPLEMENT

Caffeine capsule 250 mg, oral intake

Placebo

Intervention Type DRUG

Placebo capsule, oral intake

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Caffeine

Caffeine capsule 250 mg, oral intake

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo capsule, oral intake

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Panic Disorder group (PD): Primary diagnosis of Panic Disorder.
* Healthy control group (HCs): No current or history of psychiatric disorders.
* All participants (PD and HCs): Weekly caffeine consumption ≤ 300 mg.

Exclusion Criteria

* Weekly caffeine consumption ≥ 300 mg.
* Thoracic or head surgery, or any other surgery or metallic implanted devices not compatible with the safety standards for 7T MR scanner.
* History of severe psychiatric disorder (e.g., schizophrenia).
* Somatic or neurological conditions (e.g., hypertension and heart condition).
* Ongoing treatment with psychotropic medication or treatment with psychotropic medication which has been discontinued within 2 months.
* Other ongoing treatments that may confound the results.
* Current drug or alcohol abuse/dependency.
* Habitual nicotine use.
* Uncorrected visual or hearing impairment.
* Pregnancy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes